Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $92.50 short call and a strike $97.50 long call offers a potential 14.68% return on risk over the next 32 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $92.50 by expiration. The full premium credit of $0.64 would be kept by the premium seller. The risk of $4.36 would be incurred if the stock rose above the $97.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 21.65 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Drugmakers urge FDA security audit after cyber breach
Wed, 18 Dec 2013 01:27:22 GMT
How the major stock indexes fared on Tuesday
Tue, 17 Dec 2013 23:27:21 GMT
AP – Stocks edged lower on Tuesday as the Federal Reserve started a two-day policy meeting that may herald the beginning of the end for its economic stimulus. Few expect that the Fed will announce that it plans …
9:16 am Johnson & Johnson: Decision Diagnostics receives mandate from U.S. court of appeals for the federal circuit in the long running dispute with J&J division
Tue, 17 Dec 2013 23:04:43 GMT
Briefing.com – 9:16 am Johnson & Johnson: Decision Diagnostics receives mandate from U.S. court of appeals for the federal circuit in the long running dispute with J&J division
Keep an Eye on Biogen, Johnson & Johnson, and Merck Today
Tue, 17 Dec 2013 14:42:26 GMT
Motley Fool – Biogen, Johnson & Johnson, and Merck could all make health care headlines this morning. Here’s all the news you need to know.
Decision Diagnostics Receives Mandate From U.S. Court of Appeals for the Federal Circuit in the Long Running Dispute With J&J Division
Tue, 17 Dec 2013 14:15:00 GMT
Marketwired – Decision Diagnostics Corp. , the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip™, the unique Green Glucose Test Strip, specifically designed to work with …
Also on Market Tamer…
Follow Us on Facebook